{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T11:24:10Z","timestamp":1785929050248,"version":"3.56.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.clgc.2023.03.011","type":"journal-article","created":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T03:05:43Z","timestamp":1680231943000},"page":"459-466","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Evaluating Real-World Characteristics of Patients With Advanced Urothelial Carcinoma Eligible for Avelumab Maintenance Therapy: A Multicountry Retrospective Medical Chart Review"],"prefix":"10.1016","volume":"21","author":[{"given":"Joaquim","family":"Bellmunt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Pavilack-Kirker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9586-0748","authenticated-orcid":false,"given":"Joseph C.","family":"Cappelleri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuno","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0780-4776","authenticated-orcid":false,"given":"Elizabeth","family":"Esterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mairead","family":"Kearney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4961-0817","authenticated-orcid":false,"given":"Abigail","family":"Hitchens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean D.","family":"Candrilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayank","family":"Ajmera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2023.03.011_bib0001","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/iju.13376","article-title":"Epidemiology of urothelial carcinoma","volume":"24","author":"Miyazaki","year":"2017","journal-title":"Int J Urol"},{"key":"10.1016\/j.clgc.2023.03.011_bib0002","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clgc.2023.03.011_bib0003","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1038\/s41598-018-19199-z","article-title":"The global epidemiology of bladder cancer: a joinpoint regression analysis of its incidence and mortality trends and projection","volume":"8","author":"Wong","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.clgc.2023.03.011_bib0004","first-page":"15","article-title":"Epidemiology of bladder cancer","volume":"8","author":"Saginala","year":"2020","journal-title":"Med Sci (Basel)"},{"key":"10.1016\/j.clgc.2023.03.011_bib0005","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211047352","article-title":"Metastatic urothelial cancer: a rapidly changing treatment landscape","volume":"13","author":"Stecca","year":"2021","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.clgc.2023.03.011_bib0006","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.euo.2020.11.005","article-title":"Incidence and survival rates of contemporary patients with invasive upper tract urothelial carcinoma","volume":"4","author":"Colla Ruvolo","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.clgc.2023.03.011_bib0007","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study","volume":"18","author":"von der Maase","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2023.03.011_bib0008","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","article-title":"Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer","volume":"23","author":"von der Maase","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2023.03.011_bib0009","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S0140-6736(20)30230-0","article-title":"Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Galsky","year":"2020","journal-title":"Lancet"},{"issue":"suppl 13","key":"10.1016\/j.clgc.2023.03.011_bib0010","doi-asserted-by":"crossref","first-page":"CT042","DOI":"10.1158\/1538-7445.AM2021-CT042","article-title":"Atezolizumab (atezo)\u00a0+\u00a0platinum\/gemcitabine (plt\/gem) vs placebo\u00a0+\u00a0plt\/gem in patients (pts) with previously untreated locally advanced or metastatic urothelial carcinoma (mUC): updated overall survival (OS) from the randomized phase III study IMvigor130","volume":"81","author":"Galsky","year":"2021","journal-title":"Cancer Res"},{"key":"10.1016\/j.clgc.2023.03.011_bib0011","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S1470-2045(21)00152-2","article-title":"Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial","volume":"22","author":"Powles","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2023.03.011_bib0012","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ejca.2005.08.032","article-title":"Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours","volume":"42","author":"Sternberg","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2023.03.011_bib0013","unstructured":"NCCN Clinical Practice Guidelines in Oncology. Bladder Cancer. V1.2023."},{"key":"10.1016\/j.clgc.2023.03.011_bib0014","year":"2022"},{"key":"10.1016\/j.clgc.2023.03.011_bib0015","year":"2022"},{"key":"10.1016\/j.clgc.2023.03.011_bib0016","year":"2021"},{"key":"10.1016\/j.clgc.2023.03.011_bib0017","year":"2023"},{"key":"10.1016\/j.clgc.2023.03.011_bib0018","unstructured":"Roche press release March 8, 2021. Available at. https:\/\/www.roche.com\/media\/releases\/med-cor-2021-03-08. Accessed March 9, 2023."},{"key":"10.1016\/j.clgc.2023.03.011_bib0019","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1634\/theoncologist.2018-0084","article-title":"FDA approval summary: atezolizumab or pembrolizumab for the treatment of patients with advanced urothelial carcinoma ineligible for cisplatin-containing chemotherapy","volume":"24","author":"Suzman","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.clgc.2023.03.011_bib37","unstructured":"Tecentriq (atezolizumab) [prescribing information]: Genentech; 2022."},{"key":"10.1016\/j.clgc.2023.03.011_bib0020","year":"2021"},{"key":"10.1016\/j.clgc.2023.03.011_bib0021","year":"2021"},{"key":"10.1016\/j.clgc.2023.03.011_bib0022","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2023.03.011_bib0023","doi-asserted-by":"crossref","first-page":"243","DOI":"10.4111\/icu.20200597","article-title":"Emerging agents for the treatment of metastatic urothelial cancer","volume":"62","author":"Kwon","year":"2021","journal-title":"Investig Clin Urol"},{"key":"10.1016\/j.clgc.2023.03.011_bib0024","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.6_suppl.487","article-title":"Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): long-term follow-up results from the JAVELIN Bladder 100 trial","volume":"40","author":"Powles","year":"2022","journal-title":"J Clin Oncol"},{"issue":"Suppl 6","key":"10.1016\/j.clgc.2023.03.011_bib0025","article-title":"Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): long-term follow-up from the JAVELIN bladder 100 trial in subgroups defined by 1L chemotherapy regimen and analysis of overall survival (OS) from start of 1L chemotherapy","volume":"41","author":"Sridhar","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2023.03.011_bib0026","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.eururo.2021.09.026","article-title":"The 2021 updated European Association of Urology guidelines on metastatic urothelial carcinoma","volume":"81","author":"Cathomas","year":"2021","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.clgc.2023.03.011_bib0027","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","article-title":"Bladder cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Powles","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2023.03.011_bib0028","year":"2021"},{"key":"10.1016\/j.clgc.2023.03.011_bib0029","year":"2020"},{"key":"10.1016\/j.clgc.2023.03.011_bib0030","unstructured":"Balversa (erdafitinib) [prescribing information]: Horsham, PA: Janssen; 2019."},{"key":"10.1016\/j.clgc.2023.03.011_bib0031","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1097\/IGC.0000000000001222","article-title":"Treatment patterns and health outcomes in platinum-refractory or platinum-resistant ovarian cancer: a retrospective medical record review","volume":"28","author":"Parikh","year":"2018","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.clgc.2023.03.011_bib0032","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13044-021-00119-9","article-title":"Diagnostic characteristics, treatment patterns, and clinical outcomes for patients with advanced\/metastatic medullary thyroid cancer","volume":"15","author":"Parikh","year":"2022","journal-title":"Thyroid Res"},{"issue":"suppl 5","key":"10.1016\/j.clgc.2023.03.011_bib0033","first-page":"S678","article-title":"Treatment pattern and overall survival among patients with locally advanced or metastatic urothelial carcinoma: Results from a complete nationwide unselected real-world registry study in Denmark from 2010 to 2017","volume":"32","author":"Jensen","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2023.03.011_bib0034","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1177\/1756287216677903","article-title":"Vinflunine in the treatment of advanced urothelial cancer: clinical evidence and experience","volume":"9","author":"Gerullis","year":"2017","journal-title":"Ther Adv Urol"},{"key":"10.1016\/j.clgc.2023.03.011_bib0035","unstructured":"National Institute for Health and Care Excellence. Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy. Available at: https:\/\/www.nice.org.uk\/guidance\/ta692\/chapter\/1-Recommendations Accessed March 9, 2023"},{"key":"10.1016\/j.clgc.2023.03.011_bib0036","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/S1470-2045(20)30541-6","article-title":"Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767323000800?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767323000800?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:38:03Z","timestamp":1761565083000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767323000800"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S1558767323000800"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2023.03.011","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluating Real-World Characteristics of Patients With Advanced Urothelial Carcinoma Eligible for Avelumab Maintenance Therapy: A Multicountry Retrospective Medical Chart Review","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2023.03.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}